معرفی
Dr. Dorothy Wai is a Research Fellow in Medicinal Chemistry at Monash University's Faculty of Pharmacy and Pharmaceutical Sciences. She completed her PhD at the University of Sydney (2017), focusing on NMR-based characterization of protein-RNA interactions. Currently, her research emphasizes fragment-based drug discovery targeting neurodegenerative diseases, with a focus on developing brain-permeable peptide inhibitors for potassium channels like Kv1.3. She leads the project 'Developing potent and brain-permeable peptide therapeutics for AD' (2022-2023), demonstrating expertise in collaborative drug development.
Education: PhD in Biophysical Chemistry (University of Sydney, 2017). Research interests include structural biology, peptide therapeutics, and drug permeability optimization. Her work contributes to UN Sustainable Development Goals related to health innovation and disease treatment.
Her recent publications explore TRPV1 inhibitory peptides from marine organisms, perforin inhibitors in immunotherapy, and Kv1.3-blocking peptides' cognitive benefits in mouse models. These studies highlight interdisciplinary approaches combining biochemistry, pharmacology, and structural biology.
Grants/Projects: Primary Investigator for a 2022-2023 project on Alzheimer's therapeutics. Collaborations include work with Prof. Norton and Prof. Nicolazzo on drug development. No formal advisees listed but collaborates extensively with researchers in medicinal chemistry and structural biology.
Labs/Teams: Associated with the Monash Institute of Pharmaceutical Sciences (MIPS), focusing on translational drug discovery programs.
